Compounds > simvastatin
Page last updated: 2024-08-23

simvastatin and Diabetic Glomerulosclerosis

simvastatin has been researched along with Diabetic Glomerulosclerosis in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (12.00)18.2507
2000's11 (44.00)29.6817
2010's10 (40.00)24.3611
2020's1 (4.00)2.80

Authors

AuthorsStudies
Guan, Y; Meng, L; Sun, Z; Zhou, P1
Al-Ajmi, HN; Al-Amin, MA; Al-Rasheed, NM; Bassiouni, YA; Hasan, IH; Mahmoud, AM1
Buse, JB; Craven, TE; Ismail-Beigi, F; Katz, L; Mottl, AK; Mychaleckyj, JC; Papademetriou, V; Pedley, CF; Sigal, RJ; Simmons, DL1
Demaine, AG; Hodgkinson, AD; Millward, BA; Shaw, NA; Yang, B1
Li, C; Li, Y; Liu, X; Lou, T; Luo, P; Peng, H; Wang, C; Ye, Z1
Almquist, T; Hjemdahl, P; Jacobson, SH; Mobarrez, F; Näsman, P1
Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y1
Ho, C; Hsu, YC; Lin, CL; Tseng, CC; Wang, FS; Wang, JY1
Gao, Q; Jia, ZH; Li, LS; Liu, ZH; Qin, WS; Zeng, CH; Zheng, JM1
Chen, K; Chen, Y; Li, XC; Wang, YX; Yang, GW; Yao, XM; Ye, SD; Zai, Z1
Astrup, AS; Billestrup, N; Jacobsen, PK; Kim, WY; Lajer, M; Mandrup-Poulsen, T; Parving, HH; Pedersen, N; Reinhard, H; Rossing, P; Tarnow, L1
Martin, PY; Saudan, P1
Cao, Z; Cooper, ME; Hu, L; Liu, J; Qin, J; Sun, L; Zhang, Z1
Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC1
Hu, Y; Lin, F; Shen, H; Zhou, J; Zhu, B1
Adler, S; Chew, TL; Danesh, FR; Eng, E; Kanwar, YS; Sadeghi, MM; Xu, H; Zeng, L1
Chen, ZX; Lei, MX; Zhang, J; Zhu, LF1
Banes-Berceli, AK; Brands, M; Caldwell, RW; Eaton, DC; Fulton, D; Ma, G; Marrero, MB; Shaw, S; Stern, DM1
Hattori, H; Higuchi, S; Iida, M; Iwase, M; Ohdo, S; Sasaki, N; Sonoki, K1
Dollerup, J; Gormsen, LC; Mogensen, CE; Nellemann, B; Nielsen, S; Rasmussen, LM; Schmitz, O1
Danesh, FR; Kolavennu, V; Peng, H; Wang, Y; Zeng, L1
Atzeni, MM; Brizzi, P; Calvia, P; Ciccarese, M; Maioli, M; Melis, MG; Puddu, L; Secchi, G; Tonolo, G1
Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ1
Amro, N; Danesh, FR; Kanwar, YS; Lin, S; Philips, C; Sadeghi, MM; Sahai, A; Zeng, L1
Andersen, P; Dyerberg, J; Gall, MA; Hommel, E; Jensen, B; Nielsen, F; Parving, HH; Rossing, P1

Reviews

1 review(s) available for simvastatin and Diabetic Glomerulosclerosis

ArticleYear
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
    Kidney international. Supplement, 1999, Volume: 71

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta

1999

Trials

6 trial(s) available for simvastatin and Diabetic Glomerulosclerosis

ArticleYear
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
    Clinical journal of the American Society of Nephrology : CJASN, 2018, 11-07, Volume: 13, Issue:11

    Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Simvastatin; Time Factors

2018
Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.
    European journal of clinical investigation, 2014, Volume: 44, Issue:3

    Topics: Aged; Anticholesteremic Agents; Azetidines; Case-Control Studies; Chemokine CCL2; Cross-Over Studies; Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Inflammation; Inflammation Mediators; Interferon-gamma; Male; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2014
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Creatine Kinase; Creatine Kinase, MM Form; Creatinine; Diabetic Nephropathies; Disease Progression; Feasibility Studies; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isoenzymes; Kidney Diseases; Kidney Transplantation; Lipids; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Renal Dialysis; Renal Replacement Therapy; Simvastatin; Single-Blind Method; Thrombophilia; Treatment Outcome

2005
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
    Diabetes care, 2007, Volume: 30, Issue:12

    Topics: Albuminuria; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteoprotegerin; Simvastatin

2007
Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment.
    Diabetes care, 1997, Volume: 20, Issue:12

    Topics: Adult; Aged; Albuminuria; Anticholesteremic Agents; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Simvastatin; Time Factors

1997
Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.
    Diabetologia, 1992, Volume: 35, Issue:5

    Topics: Adult; Albuminuria; Analysis of Variance; Apolipoproteins; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Lovastatin; Male; Simvastatin; Triglycerides

1992

Other Studies

18 other study(ies) available for simvastatin and Diabetic Glomerulosclerosis

ArticleYear
Simvastatin inhibites high glucose-induced renal tubular epithelial cells apoptosis by down-regulating miR-92a.
    Pakistan journal of pharmaceutical sciences, 2021, Volume: 34, Issue:1(Special)

    Topics: Apoptosis; Cell Line; Cell Survival; Diabetic Nephropathies; Down-Regulation; Epithelial Cells; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Kidney Tubules; MicroRNAs; Simvastatin

2021
Simvastatin ameliorates diabetic nephropathy by attenuating oxidative stress and apoptosis in a rat model of streptozotocin-induced type 1 diabetes.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 105

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Body Weight; Caspase 3; Collagen; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Models, Animal; Down-Regulation; Hyperglycemia; Hypertrophy; Kidney; Kidney Function Tests; Male; Oxidative Stress; Rats, Wistar; Simvastatin; Streptozocin

2018
Protective effect of statin therapy on connective tissue growth factor induction by diabetes in vivo and high glucose in vitro.
    Growth factors (Chur, Switzerland), 2013, Volume: 31, Issue:6

    Topics: Albuminuria; Biomarkers; Cell Line, Transformed; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gene Expression Regulation; Glomerular Mesangium; Glucose; HEK293 Cells; Humans; Luciferases, Renilla; Promoter Regions, Genetic; Simvastatin; Transcription, Genetic; Transfection

2013
Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Albuminuria; Animals; Cell Line; Cell Membrane Permeability; Diabetic Nephropathies; Endothelial Cells; Gene Expression Regulation; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Mice; Mice, Transgenic; Occludin; Rats; rho GTP-Binding Proteins; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Tight Junctions; Zonula Occludens-1 Protein

2013
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
    American journal of physiology. Endocrinology and metabolism, 2015, Feb-15, Volume: 308, Issue:4

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Drug Therapy, Combination; Female; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; MicroRNAs; Muscle, Smooth, Vascular; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Renal Artery; rho-Associated Kinases; Simvastatin; Vasculitis

2015
Simvastatin alleviates diabetes-induced VEGF-mediated nephropathy via the modulation of Ras signaling pathway.
    Renal failure, 2008, Volume: 30, Issue:5

    Topics: Animals; Cells, Cultured; Diabetic Nephropathies; Glomerular Mesangium; Polyenes; Polyunsaturated Alkamides; ras Proteins; Rats; Signal Transduction; Simvastatin; Vascular Endothelial Growth Factor A

2008
Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy.
    Planta medica, 2010, Volume: 76, Issue:1

    Topics: Albuminuria; Animals; Anthraquinones; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herbal; Dyslipidemias; Extracellular Matrix; Fibronectins; Kidney; Mice; Mice, Inbred C57BL; Mice, Knockout; Phytotherapy; Rheum; Rhizome; Simvastatin; Transforming Growth Factor beta1

2010
Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression.
    Journal of endocrinological investigation, 2010, Volume: 33, Issue:5

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Gene Expression Regulation, Enzymologic; Glomerular Basement Membrane; Glycated Hemoglobin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipids; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Microscopy, Electron; Organ Size; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin

2010
Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy.
    Nephron. Clinical practice, 2011, Volume: 118, Issue:3

    Topics: Adult; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Cell Count; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Endothelial Cells; Female; Humans; Male; Mesenchymal Stem Cells; Middle Aged; Risk Factors; Simvastatin

2011
[Nephrology].
    Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323

    Topics: Anticholesteremic Agents; Azathioprine; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Failure, Chronic; Lupus Nephritis; Mycophenolic Acid; Nephrology; Renal Dialysis; Secondary Prevention; Simvastatin; Treatment Outcome

2012
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
    Kidney international, 2003, Volume: 64, Issue:2

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Losartan; Male; Rats; Rats, Wistar; Simvastatin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A

2003
Effects of simvastatin on oxidative stress in streptozotocin-induced diabetic rats: a role for glomeruli protection.
    Nephron. Experimental nephrology, 2005, Volume: 101, Issue:1

    Topics: Albuminuria; Animals; Antioxidants; Blood Glucose; Catalase; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glutathione Transferase; Hypolipidemic Agents; Kidney Glomerulus; Lipid Peroxidation; Male; Oxidative Stress; Proteinuria; Rats; Rats, Sprague-Dawley; Simvastatin; Superoxide Dismutase; Triglycerides

2005
HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:13

    Topics: Actins; Animals; Blotting, Western; Cell Line; Cytoplasm; Cytoskeleton; Cytosol; Diabetic Nephropathies; Electric Impedance; Endothelial Cells; Endothelium, Vascular; Green Fluorescent Proteins; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Mevalonic Acid; Microscopy, Confocal; Models, Biological; Models, Statistical; Myosin Light Chains; Permeability; Phosphorylation; Rats; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Transfection; Vascular Endothelial Growth Factor A

2005
[Effects of simvastatin on TGF-beta system of diabetic rat kidneys].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2005, Volume: 30, Issue:5

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Female; Kidney; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Transforming Growth Factor beta; RNA, Messenger; Simvastatin; Transforming Growth Factor beta

2005
Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells.
    American journal of physiology. Renal physiology, 2006, Volume: 291, Issue:1

    Topics: Angiotensin II; Animals; Anticholesteremic Agents; Blood Glucose; Cells, Cultured; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Janus Kinase 2; Male; Mesangial Cells; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats; Rats, Sprague-Dawley; rho GTP-Binding Proteins; Signal Transduction; Simvastatin; STAT1 Transcription Factor; STAT3 Transcription Factor; Terpenes

2006
Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.
    Atherosclerosis, 2008, Volume: 196, Issue:2

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lysophosphatidylcholines; Male; Middle Aged; Simvastatin

2008
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
    Diabetes, 2008, Volume: 57, Issue:3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Collagen Type IV; Diabetic Nephropathies; Disease Progression; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Mesangial Cells; Mice; Mice, Inbred NOD; Protein Kinase Inhibitors; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin

2008
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, Jun-11, Volume: 99, Issue:12

    Topics: Animals; Cell Differentiation; Cell Membrane; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Diabetic Nephropathies; DNA Replication; Enzyme Inhibitors; Glomerular Mesangium; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Biological; Protein Prenylation; Protein Transport; Rats; rho GTP-Binding Proteins; Signal Transduction; Simvastatin; Transfection

2002